Pamicell Secures Record-Breaking Single Order of 8.8 Billion KRW for Nucleosides

[Asia Economy Reporter Hyunseok Yoo] Pharmicell announced on the 28th that it has received an order worth approximately $7.92 million (about 8.8 billion KRW) for nucleosides from the U.S. company ThermoFisher Scientific. This is the largest single order in the company's history.

A company official stated, "The recent accelerated global demand for nucleosides is interpreted as a result of the full-scale growth of the RNA-based nucleic acid therapeutics market. Nucleosides have shown a growth rate exceeding 121% compared to the previous year through the third quarter of this year, and starting with this large order, we are also expecting continuous sales growth next year."

He added, "Due to the much steeper surge in demand than expected, we will expedite the expansion of the Ulsan plant, which was scheduled to be completed in the second half of next year, to finish it as soon as possible."

Pharmicell counts global pharmaceutical companies such as ThermoFisher Scientific in the U.S. and Merck in Europe as its major customers for nucleosides. In particular, most domestic and international pharmaceutical companies purchase raw materials through ThermoFisher Scientific. ThermoFisher recorded sales of 7.5 billion KRW by September this year, showing a 92% growth compared to last year's total sales of 3.9 billion KRW, thereby expanding its performance.

It has been confirmed that ThermoFisher and Merck process Pharmicell's nucleosides into phosphoramidites and supply them to large global pharmaceutical companies. These large pharmaceutical companies then further process them into RNA-based nucleic acid therapeutics and diagnostic kits for use.

This content was produced with the assistance of AI translation services.